Enzalutamide
- PDF / 169,112 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 70 Downloads / 169 Views
1 S
Subdural haematoma and encephalopathy owing to hypertension: 2 case reports. In a retrospective observational study involving 67 patients, conducted from March 2017 to July 2019 in Turkey, 2 men [exact ages not stated] were described, who developed subdural haematoma or encephalopathy owing to hypertension during treatment with enzalutamide for metastatic castration-resistant prostate cancer (mCRPC). The patients were diagnosed with mCRPC and enrolled in the study. The patients started receiving enzalutamide 160 mg/day [routes not stated]. Subsequently, enzalutamide was discontinued due to subdural haematoma (one patient) and encephalopathy owing to hypertension (one patient) [durations of treatment to reactions onsets and outcomes not stated]. Bilgetekin I, et al. Enzalutamide treatment in metastatic castration-resistant prostate cancer: Before and after docetaxel. Journal of the College of Physicians and Surgeons 803519214 Pakistan 30: 815-821, No. 8, Aug 2020. Available from: URL: http://doi.org/10.29271/jcpsp.2020.08.815
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
